A major multinational Biotechnology company that is driven to develop innovative medicines through the pursuit of extraordinary science was not expanding their pipeline rapidly enough. One of the causes was an inefficient process being followed by their researchers. They were recording their experiments, analyses, results, and observations in multiple systems and then combining them manually into their paper based laboratory notebooks. This process was not only causing extra work for the scientists, thereby affecting efficiency and effectiveness, but had also created a significant backlog of experimental write-ups. The missing information caused by the backlog was negatively affecting collaboration and the ability to leverage past work in current pursuits. In order to overcome these challenges, they elected to implement BIOVIA ELN across their research and development areas. CSols, Inc. was engaged to provide ELN services based on our domain, technology, and regulatory expertise.